Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017

GlobalData, September 2011, Pages: 104

Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Pneumococcal Infections - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Pneumococcal Infections market. The report identifies the key trends shaping and driving the global Pneumococcal Infections market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Pneumococcal Infections sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Pneumococcal Infections market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Pneumococcal Infections market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Pneumococcal Infections market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Pneumococcal Infections market.
- Analysis of key recent licensing and partnership agreements in Pneumococcal Infections market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Pneumococcal Infections Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Pneumococcal Infections market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Pneumococcal Infections market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Pneumococcal Infections - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.3.1 Risk Factors
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Physical Examination
2.5.2 Specimen Tests and Culture
2.5.3 Radiography
2.5.4 Blood Pressure Test
2.6 Treatment and Management Options
2.6.1 Therapeutics
2.6.2 Prophylactic
2.7 Pipeline Report Guidance
3 Pneumococcal Infections Therapeutics - Market Characterization
3.1 Pneumococcal Infections Market Size (2005-2010) - Global
3.2 Pneumococcal Infections Market Forecast (2010-2017) - Global
3.3 Pneumococcal Infections Market Size (2005-2010) - The US
3.4 Pneumococcal Infections Market Forecast (2010-2017) - The US
3.5 Pneumococcal Infections Market Size (2005-2010) - France
3.6 Pneumococcal Infections Market Forecast (2010-2017) - France
3.7 Pneumococcal Infections Market Size (2005-2010) - Germany
3.8 Pneumococcal Infections Market Forecast (2010-2017) - Germany
3.9 Pneumococcal Infections Market Size (2005-2010) - Italy
3.10 Pneumococcal Infections Market Forecast (2010-2017) - Italy
3.11 Pneumococcal Infections Market Size (2005-2010) - Spain
3.12 Pneumococcal Infections Market Forecast (2010-2017) - Spain
3.13 Pneumococcal Infections Market Size (2005-2010) - The UK
3.14 Pneumococcal Infections Market Forecast (2010-2017) - The UK
3.15 Pneumococcal Infections Market Size (2005-2010) - Japan
3.16 Pneumococcal Infections Market Forecast (2010-2017) - Japan
3.17 Drivers and Barriers for the Pneumococcal Infections Market
3.17.1 Drivers for the Pneumococcal Infections Market
3.17.2 Barriers for the Pneumococcal Infections Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Pneumococcal Infections - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for Major Marketed Products in the Pneumococcal Infections Market
4.2.1 Prevnar7
4.2.2 Prevnar13 (pneumococcal 13-valent conjugate vaccine)
4.2.3 Pneumovax 23
4.2.4 Synflorix
4.2.5 Beta-lactam (ß-lactam) antibiotics
4.2.6 Penicillin Antibiotic
4.2.7 Cephalosporin Antibiotic
4.2.8 Glycopeptide Antibiotics
4.2.9 Lincosamide
4.2.10 Zyvox (linezolid)
4.2.11 Zosyn (piperacillin and tazobactam)
4.2.12 Levaquin (levofloxacin)
4.2.13 Avelox (moxifloxacin)
4.2.14 Tygacil (tigecycline)
4.3 Comparison of Pneumococcal Infections Vaccines
4.4 Key Takeaway
5 Pneumococcal Infections - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Pneumococcal Infections Pipeline - Pipeline by Phases of Development
5.3.1 Pneumococcal Infections - Regulatory Filed Products
5.3.2 Pneumococcal Infections - Phase III Pipeline
5.3.3 Pneumococcal Infections - Phase II Pipeline
5.3.4 Pneumococcal Infections - Phase I Pipeline
5.3.5 Pneumococcal Infections - Discovery and Pre-Clinical Pipeline
5.3.6 Technology Trends Analytic Framework
5.4 Pneumococcal Infections Market - Clinical Pipeline by Mechanism of Action
5.5 Pneumococcal Infections - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Ceftobiprole
5.6.2 Restanza
5.6.3 Torezolid phosphate (TR-701, DA-7218)
5.6.4 Vibativ (televancin)
5.7 Key Takeaway
6 Pneumococcal Infections - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Pneumococcal Infections Clinical Trials
7 Pneumococcal Infections - Strategic Assessment
7.1 Key Events Affecting the Future Market
7.2 Pneumococcal Infections - Implications for Future Market Competition
8 Pneumococcal Infections - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 GlaxoSmithKline plc
8.2.2 Merck & Co., Inc.
8.2.3 Pfizer Inc.
8.2.4 Trius Therapeutics
8.2.5 Furiex Pharmaceuticals, Inc
8.2.6 Theravance, Inc.
8.2.7 Cempra Pharmaceuticals, Inc.
8.2.8 Advanced Life Sciences Holdings, Inc
8.2.9 Basilea Pharmaceutica Ltd
8.2.10 Other Companies in the Pneumococcal Infections Market
9 Pneumococcal Infections - Licensing and Partnership Deals
10 Pneumococcal Infections - Appendix
10.1 Market Definitions
10.2 Abbreviationsl
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Types of Pneumococcal Infections
Table 2: Signs and Symptoms of Common Pneumococcal Infections
Table 3: Treatment for Pneumococcal Infections
Table 4: Pneumococcal Infections Market, Global, Revenue ($m), 2005-2010
Table 5: Pneumococcal Infections Market, Global, Forecast ($m), 2010-2017
Table 6: Pneumococcal Infections Market, The US, Revenue ($m), 2005-2010
Table 7: Pneumococcal Infections Market, The US, Forecast ($m), 2010-2017
Table 8: Pneumococcal Infections Market, France, Revenue ($m), 2005-2010
Table 9: Pneumococcal Infections Market, France, Forecast ($m), 2010-2017
Table 10: Pneumococcal Infections Market, Germany, Revenue ($m), 2005-2010
Table 11: Pneumococcal Infections Market, Germany, Forecast ($m), 2010-2017
Table 12: Pneumococcal Infections Market, Italy, Revenue ($m), 2005-2010
Table 13: Pneumococcal Infections Market, Italy, Forecast ($m), 2010-2017
Table 14: Pneumococcal Infections Market, Spain, Revenue ($m), 2005-2010
Table 15: Pneumococcal Infections Market, Spain, Forecast ($m), 2010-2017
Table 16: Pneumococcal Infections Market, The UK, Revenue ($m), 2005-2010
Table 17: Pneumococcal Infections Market, The UK, Forecast ($m), 2010-2017
Table 18: Pneumococcal Infections Market, Japan, Revenue ($m), 2005-2010
Table 19: Pneumococcal Infections Market, Japan, Forecast ($m), 2010-2017
Table 20: Pneumococcal Infection Therapeutics - Penicillin Antibiotics by Classification, 2011
Table 21: Cure Rates of Zyvox in Nosocomial Pneumonia (%), 2011
Table 22: Cure Rates of Zyvox in Community-Acquired Pneumonia due to MDRSP (%), 2011
Table 23: Pneumococcal Vaccines
Table 24: Pneumococcal Infections - Regulatory Filed Products, 2011
Table 25: Pneumococcal Infections - Phase III Pipeline, 2011
Table 26: Pneumococcal Infections - Phase II Pipeline, 2011
Table 27: Pneumococcal Infections - Phase I Pipeline, 2011
Table 28: Pneumococcal Infections Therapeutics - Discovery and Pre-Clinical Pipeline, 2011
Table 29: Pneumococcal Infections - Most Promising Drugs Under Clinical Development, 2011
Table 30: Status of Ceftobiprole
Table 31: Pneumococcal Infections - Clinical Trials by Country, 2011
Table 32: Pneumococcal Infections - Clinical Trials by Phase, 2011
Table 33: Pneumococcal Infections - Clinical Trials by Status, 2011
Table 34: Pneumococcal Infections - Prominent Sponsors, 2011
Table 35: Pneumococcal Infections - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 36: GlaxoSmithKline Plc. - Infectious Diseases, Pipeline, 2011
Table 37: Merck &Co. Infectious Diseases, Pipeline, 2011
Table 38: Pfizer - Infectious Disease , Pipeline, 2011
Table 39: Trius Therapeutics-Infectious Disease , Pipeline, 2011
Table 40: Furiex Pharmaceuticals-Infectious Disease , Pipeline, 2011
Table 41: Theravance Inc. - Infectious Disease , Pipeline, 2011
Table 42: Cempra Pharmaceuticals- Infectious Disease , Pipeline, 2011
Table 43: Advanced Life Sciences Holdings ,Inc - Infectious Disease , Pipeline, 2011
Table 44: Basilea Pharmaceutica - Infectious Disease , Pipeline, 2011
Table 45: Pneumococcal Infections Market - Future Players
Table 46: Pneumococcal Infections, Global, Deals, 2011

1.2 List of Figures
Figure 1: Risk of Pneumococcal Infection
Figure 2: Pneumococcal Infections Prophylactic Market, Global, Revenue ($m), 2005-2010
Figure 3: Pneumococcal Infections Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 4: Pneumococcal Infections Prophylactic Market, Global, Forecast ($m), 2010-2017
Figure 5: Pneumococcal Infections Therapeutics Market, Global, Forecast ($m), 2010-2017
Figure 6: Pneumococcal Infections Prophylactic Market, The US, Revenue ($m), 2005-2010
Figure 7: Pneumococcal Infections Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 8: Pneumococcal Infections Prophylactic Market, The US, Forecast ($m), 2010-2017
Figure 9: Pneumococcal Infections Therapeutics Market, The US, Forecast ($m), 2010-2017
Figure 10: Pneumococcal Infections Prophylactic Market, France, Revenue ($m), 2005-2010
Figure 11: Pneumococcal Infections Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 12: Pneumococcal Infections Prophylactic Market, France, Forecast ($m), 2010-2017
Figure 13: Pneumococcal Infections Therapeutics Market, France, Forecast ($m), 2010-2017
Figure 14: Pneumococcal Infections Prophylactic Market, Germany , Revenue ($m), 2005-2010
Figure 15: Pneumococcal Infections Therapeutics Market, Germany , Revenue ($m), 2005-2010
Figure 16: Pneumococcal Infections Prophylactic Market, Germany , Forecast ($m), 2010-2017
Figure 17: Pneumococcal Infections Therapeutics Market, Germany , Forecast ($m), 2010-2017
Figure 18: Pneumococcal Infections Prophylactic Market, Italy, Revenue ($m), 2005-2010
Figure 19: Pneumococcal Infections Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 20: Pneumococcal Infections Prophylactic Market, Italy, Forecast ($m), 2010-2017
Figure 21: Pneumococcal Infections Therapeutics Market, Italy, Forecast ($m), 2010-2017
Figure 22: Pneumococcal Infections Prophylactic Market, Spain, Revenue ($m), 2005-2010
Figure 23: Pneumococcal Infections Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 24: Pneumococcal Infections Prophylactic Market, Spain, Forecast ($m), 2010-2017
Figure 25: Pneumococcal Infections Therapeutics Market, Spain, Forecast ($m), 2010-2017
Figure 26: Pneumococcal Infections Prophylactic Market, The UK, Revenue ($m), 2005-2010
Figure 27: Pneumococcal Infections Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 28: Pneumococcal Infections Prophylactic Market, The UK, Forecast ($m), 2010-2017
Figure 29: Pneumococcal Infections Therapeutics Market, The UK, Forecast ($m), 2010-2017
Figure 30: Pneumococcal Infections Prophylactic Market, Japan, Revenue ($m), 2005-2010
Figure 31: Pneumococcal Infections Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 32: Pneumococcal Infections Prophylactic Market, Japan, Forecast ($m), 2010-2017
Figure 33: Pneumococcal Infections Therapeutics Market, Japan, Forecast ($m), 2010-2017
Figure 34: Opportunity and Unmet Need in the Pneumococcal Infections Prophylactic Market
Figure 35: Opportunity and Unmet Need in the Pneumococcal Infections Therapeutics Market
Figure 36: Pneumococcal Infections Prophylactic - Strategic Competitor Assessment, 2011
Figure 37: Pneumococcal Infections Therapeutics - Strategic Competitor Assessment, 2011
Figure 38: Pneumococcal Infections - Pipeline by Phase of Development (%), 2011
Figure 39: Pneumococcal Infections - Technology Trends Analytics Framework, 2011
Figure 40: Pneumococcal Infections - Technology Trends Analytics Framework - Description, 2011
Figure 41: Pneumococcal Infections - Pipeline by Mechanism of Action (%), 2011
Figure 42: Pneumococcal Infections - Clinical Trials by Country, 2011
Figure 43: Pneumococcal Infections - Clinical Trials by Phase (%), 2011
Figure 44: Pneumococcal Infections - Clinical Trials by Status (%), 2011
Figure 45: Pneumococcal Infections - Overall Sponsors (%), 2011
Figure 46: Pneumococcal Infections - Prominent Sponsors (%), 2011
Figure 47: Pneumococcal Infections - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 48: Pneumococcal Infections Market, Drivers and Restraints, 2011
Figure 49: Implications for Future Market Competition in the Pneumococcal Infections Market, 2011
Figure 50: Pneumococcal Infections Therapeutics Market - Pipeline by Company, 2011
Figure 51: Market Forecasting Model

GlaxoSmithKline plc
Merck & Co., Inc.
Pfizer Inc.
Trius Therapeutics
Furiex Pharmaceuticals, Inc
Theravance, Inc.
Cempra Pharmaceuticals, Inc.
Advanced Life Sciences Holdings, Inc
Basilea Pharmaceutica Ltd

Customers who bought this item also bought

• Global Pneumococcal Infections Drug Pipeline Capsule - 2011
• Global Pneumococcal Infections Drug Pipeline Capsule - 2012
• Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
• Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010
• Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2018
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• Herpes Simplex Virus Treatment - Global Strategic Business Report
• Competitor Analysis: Pneumococcal and Streptococcal Vaccines
• Intranasal Drug Delivery - Global Business Strategic Report